List of Adzenys Er drug patents

Adzenys Er is owned by Neos Theraps Inc.

Adzenys Er contains Amphetamine.

Adzenys Er has a total of 3 drug patents out of which 0 drug patents have expired.

Adzenys Er was authorised for market use on 15 September, 2017.

Adzenys Er is available in suspension, extended release;oral dosage forms.

The generics of Adzenys Er are possible to be released after 28 June, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic